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Background
Bortezomib has significant activity in treating multiple myeloma (MM). The risk of herpes 
zoster (HZ) has been reported to increase significantly with bortezomib treatment, but 
the predisposing factors for HZ are not clear. This study is a retrospective analysis of the 
relevant risk factors for HZ in Korean MM patients treated with bortezomib.
Methods 
Sixty-six patients with refractory or relapsed MM who underwent chemotherapy with 
bortezomib were included in the study. Prophylactic antiviral drugs were not used for 
treatment. The following parameters were reviewed: age, gender, stage and type of MM, 
extent of previous treatment, history of HZ, duration from the time of diagnosis to the 
time of bortezomib treatment initiation, and absolute lymphocyte counts (ALC) at the 
time of bortezomib treatment initiation. 
Results
The incidence of HZ was 16.7%. There were no intergroup differences between the 
HZ-positive and the HZ-negative groups with regard to a history of HZ, number of pre-
vious treatments, and exposure to steroids before bortezomib treatment. The median du-
ration from the time of MM diagnosis to the time of bortezomib treatment initiation in 
the HZ-positive group was significantly shorter than that in the HZ-negative group. The 
median ALC at the time of bortezomib initiation in the HZ-positive group was significantly 
lower than that in the HZ-negative group.
Conclusion 
Bortezomib itself might act as a risk factor for HZ by inhibiting cell-mediated immunity, 
and patients with low ALC at the time of bortezomib treatment initiation were at greater 
risk of HZ during bortezomib treatment.
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INTRODUCTION
  Multiple myeloma (MM) is characterized by the malignant 
proliferation of a plasma cell originating from a single clone 
and is associated with innate impairment of humoral im-
munity rather than cell-mediated immunity. In addition, 
in patients with MM, treatment-associated immunodefici-
ency increases the susceptibility to various infections.
  Bortezomib, introduced in the late 1990s, has significant 
activity against MM and is one of the most widely used 
drugs in the treatment of MM. As a proteosome inhibitor, 
bortezomib directly induces apoptosis of myeloma cells and 
acts in the bone marrow microenvironment, inhibits myelo-
ma cells binding to bone marrow stromal cells, alters cytokine 
secretion, and restricts angiogenesis [1-3]. Notably, the risk 
of HZ was significantly higher in patients treated with 
bortezomib. In the Assessment of Proteasome Inhibition for 
Extending Remissions APEX study, the incidence of HZ after 
bortezomib treatment was significantly higher than that after Korean J Hematol 2010;45:188-92.
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Table 1. Comparison of patient characteristics between HZ-positive group and HZ-negative group at the time of diagnosis of multiple myeloma.
Clinical and laboratory characteristics HZ-positive group (N=12) HZ-negative group (N=54) P
At the time of diagnosis 
  Median age, years (range)  61.5 (40-76) 63.5 (44-78) 0.549
  Sex, N (%) 0.295
    Male      8 (66.7)    27 (50)
    Female       4 (33.3)    27 (50)
  ECOG, N (%) 0.426
    0/1    10 (83.3)    39 (72.2)
    2/3      2 (16.7)    15 (27.8)
  Type of myeloma, N (%) 0.457
    IgG      5 (41.7)    30 (55.6)
    IgA      3 (25.0)    13 (24.1)
    IgM      0 (0)      1 (1.8)
    IgD      0 (0)      1 (1.8)
    Light chain      4 (33.3)      6 (11.1)
    Nonsecretory      0 (0)      0 (0)
    Unknown      0 (0)      3 (5.6)
  International staging system, N (%) 0.060
    I      2 (16.7)      4 (7.4)
    II      1 (8.3)    24 (44.4)
    III      9 (75.0)    26 (48.1)
  Laboratory findings
    Median serum M protein (range), g/dL      5 (3.03-9.09)   4.5 (0.23-9.81) 0.214
    Median β2MG (range), μg/mL    6.5 (3.28-15.83)   5.0 (1.75-39.3) 0.572
    Median serum albumin (range), g/dL   3.5 (2.4-4.6)   3.0 (1.6-4.8) 0.073
    Median serum creatinine (range), mg/dL   1.5 (0.6-2.6)   1.0 (0.5-9.0) 0.577
    Median Hb (range), g/dL   8.5 (7.8-12.9)   9.0 (5.3-14.9) 0.888
Abbreviations: HZ, herpes zoster; ECOG, eastern cooperative oncology group; β2MG, β2-microglobulin.
dexamethasone treatment (13% vs. 5%, P＜0.001) [4]. Other 
studies have reported the incidence of bortezomib-treatment 
associated HZ to be as high as 10-22.3% [5-11].
  The predisposing factors to HZ during bortezomib treat-
ment are not clear. History of HZ, performance status (PS), 
age, sex, disease stage, baseline β2-microglobulin levels, Hb, 
platelets, ALC, absolute neutrophil count (ANC), the fre-
quency of prior therapies, and disease duration prior to ini-
tiation of bortezomib treatment did not show any associations 
with HZ development [4, 8].
  Therefore, we aimed to perform a retrospective analysis 
investigating the incidence and the relevant risk factors for 
HZ development in Korean MM patients undergoing borte-
zomib treatment.
MATERIALS AND METHODS
  From 3 cent ers located in t he So uthern part  of  the Republic 
of Korea, 73 patients previously diagnosed with MM (July 
1998-December 2009) and treated with bortezomib-contain-
ing chemotherapy were selected for the study. Seven patients 
were excluded due to the absence of follow-up (n=1) or 
initial (n=6) data, and the latter 6 did not develop HZ. A 
total of 66 patients were included in the study.
  Bortezomib was used as a single agent or combined with 
other drugs such as dexamethasone, doxorubicin, cyclo-
phosphamide, or thalidomide. The patients all had refractory 
or relapsed MM, and were given bortezomib as a salvage 
therapy. Prophylactic antiviral drugs were not used. Patients 
who developed HZ during the bortezomib treatment were 
identified.
  At the time of MM diagnosis, the following parameters 
were recorded: age, gender, the Eastern Cooperative 
Oncology Group (ECOG) PS, the international staging sys-
tem, type and level of heavy chain and light chains, serum 
β2-microglobulin, albumin, creatinine, Hb, WBC, ANC, 
ALC, and platelet counts. The potential risk factors that 
may predispose patients to HZ were also recorded at the 
initiation of bortezomib treatment: HZ history, frequency 
of prior treatments, past steroid exposure, median duration 
from MM diagnosis to bortezomib initiation, serum β2-mi-
croglobulin, albumin, creatinine, Hb, WBC, ANC, ALC, and 
any other drugs combined with bortezomib.
  The clinical and laboratory characteristics of HZ-positive 
and HZ-negative groups were compared using chi-square 
test and Wilcoxon rank sum test. Statistical significance was 
defined as P＜0.05. All statistical analyses were performed 
using SPSS software (version 15.0; SPSS Inc., Chicago, IL, 
USA).Korean J Hematol 2010;45:188-92.
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Table 2. Comparison of patient characteristics between HZ-positive group and HZ-negative group at the initiation of bortezomib treatment.
Clinical and laboratory characteristics HZ-positive group (N=12) HZ-negative group (N=54) P
At the time of initiation of bortezomib treatment 
  HZ history, N (%) 0.554
    Present      1 (8.3)      8 (14.9)
    Absent     11 (91.7)    46 (85.1)
  Prior treatment, N (%) 0.666
    0      0 (0)      0 (0)
    1      6 (50.0)    25 (46.3)
    2      3 (25.0)    20 (37.0)
    ≥3      3 (25.0)      9 (16.7)
  Prior treatment with steroids, N (%) 0.403
    Present    12 (100.0)    51 (94.4)
    Absent      0 (0)      3 (5.6)
  Median duration from the time of diagnosis to the 10.5 (2-36)    24 (2-98) 0.002
   time of bortezomib initiation, months (range)
  Laboratory findings
    Median serum M protein (range), g/dL   3.0 (0.48-9.64)   2.5 (0.10-9.63) 0.849
    Median β2MG (range), μg/mL    7.0 (3.15-20.0)   4.0 (1.86-20.0) 0.128
    Median serum albumin (range), g/dL   3.5 (2.0-4.7)   3.5 (1.3-5.0) 0.479
    Median serum creatinine (range), mg/dL   1.5 (0.6-5.2)   1.0 (0.5-6.8) 0.144
    Median Hb (range), g/dL   8.5 (4.9-11.9) 10.0 (7.1-15.8) 0.071
    Median ANC (range), ×10
9/L   3.5 (0.98-7.04)   2.5 (0.45-9.35) 0.258
    Median ALC (range), ×10
9/L   1.0 (0.43-1.50)   1.5 (0.27-3.20) 0.018
  Bortezomib regimen, n (%) 0.119
    Bortezomib      1 (8.3)      5 (9.3)
    Bortezomib/dexamethasone      6 (50.0)    38 (70.4)
    Bortezomib/doxorubicin/dexamethasone      0 (0)      3 (5.6)
    Bortezomib/cyclophosphamide/dexamethasone      2 (16.7)      6 (11.1)
    Bortezomib/cyclophosphamide/thalidomide/dexamethasone      2 (16.7)      2 (3.7)
    Bortezomib/thalidomide/dexamethasone      1 (8.3)      0 (0)
  Bortezomib regimen with Dexamethasone, N (%) 0.920
    Present    11 (91.7)    49 (90.7)
    Absent      1 (8.3)      5 (9.3)
Abbreviations: HZ, herpes zoster; β2MG, β2-microglobulin.
RESULTS
1. HZ incidence and characteristics during bortezomib treat-
ment
  The incidence of HZ during bortezomib treatment was 
16.7% (12/66 patients). The median duration from bortezo-
mib treatment initiation to HZ onset was 2 months (range, 
1-13 months). In 1 patient, HZ took longer than 6 months 
to develop (13 months), whereas in the remaining 11 patients, 
HZ developed within 6 months of the initial bortezomib 
administration. The patient with the 13-month interval time 
received 10 cycles of bortezomib in combination with dex-
amethasone for 28 months until disease progression 
developed. Nine of the 12 patients (75%) resumed bortezomib 
after receiving HZ treatment. The remaining 3 patients (25%) 
discontinued bortezomib treatment for reasons of disease 
progression, self-refusal, and poor PS, respectively.
2. Patient characteristics at MM diagnosis
  The median age, gender, ECOG PS, disease type, and stage 
of disease did not account for significant differences between 
the HZ-positive and HZ-negative groups (Table 1). Laboratory 
parameters such as the median serum M protein, β2-micro-
globulin, albumin, creatinine, and Hb were similar between 
the 2 groups.
3. Patient characteristics at bortezomib treatment initiation
  A history of HZ prior to bortezomib treatment in the 
HZ-positive group occurred no more frequently than in the 
HZ-negative group (8.3% vs. 14.9%, P=0.554) (Table 2). Thus, 
a history of HZ at the initiation of bortezomib treatment 
may have no influence on HZ occurrence during bortezomib 
treatment.
  Although all patients previously received more than 1 
treatment, the number of treatments prior to bortezomib 
initiation did not significantly associate with HZ incidence 
(P=0.119). The rate of steroid exposure did not differ sig-
nificantly between the two groups. However, in the HZ-pos-
itive group, the median duration from MM diagnosis to the 
initiation of bortezomib treatment was significantly shorter 
when compared to the HZ-negative group (10.5 vs. 24 
months,  P=0.002) (Fig. 1).
  No significant differences were detected in laboratory pa-
rameters (e.g., serum M protein level, β2-microglobulin, al-
bumin, creatinine, Hb, and ANC) at the initiation of bortezo-Korean J Hematol 2010;45:188-92.
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Fig. 2. Median ALC at the time of bortezomib treatment initiation in the
herpes zoster-positive and herpes zoster-negative groups. The median 
absolute lymphocyte counts (ALC) at the time of bortezomib initiation 
in the herpes zoster-positive group was significantly lower than that in 
the herpes zoster-negative group (P=0.018).
Fig. 1. Median duration from the time of diagnosis to the time of 
bortezomib treatment initiation (months) in the herpes zoster-positive
and herpes zoster-negative groups. The interval between the time of 
diagnosis and the time of bortezomib treatment initiation in the herpes 
zoster-positive group was significantly shorter than that in the herpes 
zoster-negative group (P=0.002).
mib treatment. However, the median ALC at bortezomib 
treatment initiation was significantly lower in the HZ-pos-
itive group (1.12×10
9/L vs. 1.57×10
9/L,  P=0.018) (Fig. 2).
  In both groups, more than half of the patients were given 
bortezomib in combination with dexamethasone. Neither 
dexamethasone nor other drugs used in combination with 
bortezomib were significantly associated with HZ occurrence 
during treatment.
DISCUSSION
  HZ commonly occurs in elderly and immunocompromised 
individuals, and is associated with decreased cell-mediated 
immunity [12]. In immunocompromised individuals, partic-
ularly in those with impaired cell-mediated immunity, HZ 
can disseminate and cause more serious organ involvement, 
including hepatitis, pneumonia, and encephalitis [12]. 
However, impaired innate immunity in myeloma primarily 
affects humoral immunity rather than cell-mediated im-
munity; therefore, patients with MM were not at increased 
risk for HZ [13].
  Bortezomib is one of the most widely used drugs for treat-
ing MM, and it is effective as one of the first-line regimen 
in previously untreated myeloma patients [7] as well as the 
second-line regimen in relapsed or refractory patients 
[14-16].
  Several studies have indicated increased HZ risk during 
bortezomib treatment. In a phase III APEX trial, the in-
cidence of HZ significantly increased in the bortezomib 
group compared to the high-dose dexamethasone group in 
relapsed MM patients [4]. Other studies identified an associa-
tion between bortezomib and increased HZ incidence in 
the range of 10-22.3% in relapsed MM [6, 8, 10, 11]. The 
overall HZ incidence in the present study was 16.7% in 
patients with refractory or relapsed MM, which is com-
parable to previous studies.
  In addition to myeloma-related immunodeficiency and 
its complications, cumulative immunosuppression by salvage 
therapy may also increase susceptibility to infection. 
However, the present study showed a significantly shorter 
duration from MM diagnosis to bortezomib treatment ini-
tiation in the HZ-positive group compared to the HZ-neg-
ative group, identical to data reported in the previous study 
[8], suggesting that disease duration is not a risk factor for 
zoster development. This result is supported by several recent 
studies on bortezomib-associated HZ in newly diagnosed 
myeloma patients. The incidence of HZ during bortezomib 
treatment in newly diagnosed patients is similar to HZ in-
cidence in relapsed or refractory cases, in the range of 13-20% 
[5, 7, 9, 17].
  Several experimental studies have shown that bortezomib 
decreases the number and function of CD56+ NK cells and 
CD8+ cytotoxic T cells, with no definite decrease in CD4+ 
T cells [18], and it inhibits the function of dendritic cells 
[19]. Bortezomib targets the 26S proteasome and thereby 
prevents the activation of nuclear factor (NF)-κB, which 
then leads to inhibition of T cell activation as well as an-
ti-myeloma effects [20]. Although mechanisms are not clear, 
this may lead to impaired cell-mediated immunity such as 
above. Thus, the use of bortezomib might itself act as a 
predisposing factor to HZ. In the present study, the median 
ALC at bortezomib treatment initiation in the HZ-positive 
group was significantly lower than in the HZ-negative group. 
Although no lymphocyte subset or other immune cell data 
has been acquired and the sample size is small, the decreased 
ALC at bortezomib treatment initiation may reflect increased 
risk for the development of HZ during bortezomib treatment.Korean J Hematol 2010;45:188-92.
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  Although untreated MM patients were not at increased 
risk for HZ [13], HZ was more likely to occur following 
dexamethasone-based regimens due to decreased cell-medi-
ated immunity [17]. However, as shown in the phase III 
APEX trial, the incidence of HZ was significantly higher 
in the bortezomib group despite the comparable ALC baseline 
levels detected in bortezomib-treated patients with HZ and 
dexamethasone-treated patients with HZ [4]. The incidence 
of Candida and other fungal infections was significantly high-
er in the dexamethasone group, and the overall incidence 
of infection was similar between the two groups [4]. These 
results suggest that bortezomib and dexamethasone have 
different immunosuppressive properties, and the associated 
HZ development may involve more than the degree of 
lymphocytopenia.
  In conclusion, the use of bortezomib itself is a risk factor 
for HZ because it inhibits T cell activation and impairs 
cell-mediated immunity. Clinically, patients who presented 
decreased ALC at the initiation of bortezomib treatment 
were associated with HZ development. Future studies will 
focus on serial changes of the specific lymphocyte subsets 
and other immune cells that affect zoster development, and 
on the strategy of prophylaxis.
REFERENCES
1. Curran MP, McKeage K. Bortezomib: a review of its use in patients 
with multiple myeloma. Drugs 2009;69:859-88. 
2. Hideshima T, Richardson P, Chauhan D, et al. The proteasome in-
hibitor PS-341 inhibits growth, induces apoptosis, and overcomes 
drug resistance in human multiple myeloma cells. Cancer Res 
2001;61:3071-6. 
3. Richardson PG, Hideshima T, Anderson KC. Bortezomib 
(PS-341): a novel, first-in-class proteasome inhibitor for the treat-
ment of multiple myeloma and other cancers. Cancer Control 
2003;10:361-9. 
4. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of 
herpes zoster events among bortezomib-treated patients in the 
phase III APEX study. J Clin Oncol 2008;26:4784-90.
5. Mateos MV, Hernández JM, Hernández MT, et al. Bortezomib 
plus melphalan and prednisone in elderly untreated patients with 
multiple myeloma: results of a multicenter phase 1/2 study. Blood 
2006;108:2165-72. 
6. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, mel-
phalan, prednisone, and thalidomide for relapsed multiple 
myeloma. Blood 2007;109:2767-72. 
7. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus mel-
phalan and prednisone for initial treatment of multiple myeloma. 
N Engl J Med 2008;359:906-17. 
8. Kim SJ, Kim K, Kim BS, et al. Bortezomib and the increased in-
cidence of herpes zoster in patients with multiple myeloma. Clin 
Lymphoma Myeloma 2008;8:237-40. 
9. Zheng W, Wei G, Ye X, et al. Bortezomib in combination with dex-
amethasone and subsequent thalidomide for newly-diagnosed 
multiple myeloma: a Chinese experience. Leuk Res 2009;33: 
1615-8. 
10. Ohguchi H, Sugawara T, Ishikawa I, et al. A retrospective analysis 
of bortezomib therapy for Japanese patients with relapsed or re-
fractory multiple myeloma: beta2-microglobulin associated with 
time to progression. Int J Hematol 2009;89:342-7. 
11. Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and 
dexamethasone in advanced multiple myeloma. Ann Oncol 
2008;19:1160-5. 
12. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, 
Griffiths PD. Advances in the understanding of the pathogenesis 
and epidemiology of herpes zoster. J Clin Virol 2010;48(Suppl 
1):S2-7. 
13. Morison WL. Letter: herpes simplex and herpes zoster in 
neoplasia. Lancet 1974;1:1293. 
14. Richardson PG, Sonneveld P, Schuster M, et al. Extended fol-
low-up of a phase 3 trial in relapsed multiple myeloma: final 
time-to-event results of the APEX trial. Blood 2007;110:3557-60. 
15. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two 
doses of bortezomib in relapsed or refractory myeloma. Br J 
Haematol 2004;127:165-72. 
16. Richardson PG, Barlogie B, Berenson J, et al. phase 2 study of borte-
zomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 
2609-17.
17. Nucci M, Anaissie E. Infections in patients with multiple myeloma 
in the era of high-dose therapy and novel agents. Clin Infect Dis 
2009;49:1211-25. 
18. Uy GL, Peles S, Fisher NM, Tomasson MH, DiPersio JF, Vij R. 
Bortezomib prior to autologous transplant in multiple myeloma: 
effects on mobilization, engraftment, and markers of immune 
function. Biol Blood Marrow Transplant 2006;12(Suppl 1):116. 
19. Nencioni A, Garuti A, Schwarzenberg K, et al. Proteasome in-
hibitor-induced apoptosis in human monocyte-derived dendritic 
cells. Eur J Immunol 2006;36:681-9. 
20. Matsumoto M, Yamada T, Yoshinaga SK, et al. Essential role of 
NF-kappa B-inducing kinase in T cell activation through the 
TCR/CD3 pathway. J Immunol 2002;169:1151-8.